This Is MS Multiple Sclerosis Knowledge & Support Community

Bob, I'm lighting some candles in my snow cave right now.

Jimmy, I'm sending the dog sled by to pick you up.

Sharon, do you think DHEA has any potential?

Rainer, don't worry, the rest of us can keep being jerks, I was just talking to big meanie Bob.

I came back to post this to find Bromley's thread is locked. But as an act of faith in the better aspects of human nature, I just wanted to provide a link to the original research article on which the BBC story in Ian's post was based. I hope the link works... http://www.nature.com/neuro/journal/vao...

GeNeuro is a company that has been mentioned a couple of times at TIMS. They have been working on a monoclonal antibody against MSRV/HERV-W, the MS-associated endogenous retrovirus. According to the pdf document below, they are now gearing up for a clinical trial starting early next year. Of course ...

The abstract below describes another new way of classifying MS. I like it because it blasts EAE right off the top. On the other hand their condemnation of immunosuppression seems too broad to me since there are some successes on that front (campath etc.) Also, their comments about the placebo effect...

Thanks for posting those Sharon. Always an interesting read.

mrsjitters, I'm no doctor, but exercise typically doesn't cause relapses. If it was an existing symptom made worse by exercising, I'd guess that you're having a heat response (body temperature rise leading to activation of symptoms, but not a relapse). I have no idea whether your headaches / ear pai...

Interesting research that could help explain the process of gray matter neurodegeneration. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2010 Nov 8. [Epub ahead of print] Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull...

They are definitely moving this one along. I moved ocrelizumab to phase 3 on the pipeline list as they are starting a phase 3 trial for primary progressive MS.

http://www.clinicaltrials.gov/ct2/show/NCT01194570

I added a PPMS trial of Ocrelizumab to the phase 3 list, based on this clinicaltrials.gov listing . On the one hand, this is GREAT news! Any time a new substance enters phase 3 it's a major step in the right direction. Just as importantly, it is being tested for PPMS, where the need is greatest. On ...

For what it's worth, here's a recent Pubmed abstract reviewing ASCT results for MS patients: PATU8 Analysis of outcomes of high-dose immunosuppressive therapy with autologous stem cell transplantation in 156 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):e26. Novik ...

Well, I just finished going through the phase 1 list and removed a few things. There are only 14 substances in phase 1 now. Hopefully there is a lot out there that I am missing...

I moved Amiloride from phase 1 to phase 2 (and it's a primary progressive trial!) based on this: The primary objective of the study is to evaluate the effects of the drug, oral amiloride in primary progressive Multiple Sclerosis (MS) patients during 12 months of treatment. This project aims to evalu...

Here is the ECTRIMS abstract: Epicutaneous immunisation with myelin peptides induces a unique population of tolerogenic dendritic cells in lymph nodes of multiple sclerosis patients M. Jurynczyk, A. Walczak, A. Jurewicz, D. Jesionek-Kupnicka, M. Szczepanik, K. Selmaj (Lodz, Cracow, PL) Antigen-speci...

Scorpion, I guess they were doing a trial, so they wanted to see it through, but a similar trial had negative results, reported at the AAN meeting back in 2007: A Double Blind, Placebo Controlled Trial of Atorvastatin in Combination with Subcutaneous Interferon Beta 1a in Persons with Multiple Scler...

That's great to hear Wesley. I imagine that you've exposed your theory to a lot of smart people who have had a chance to poke holes in it. So if it's still afloat, that has to be a good sign. Good luck with further development.